Skip to main content

Codexis, Inc.

corporate_fare Company Profile

Codexis, Inc.

CDXS·NASDAQ·Industrial Applications And Services·CIK 0001200375

Company X is a leading provider of technology solutions for improving therapeutics manufacturing. The company utilizes its proprietary CodeEvolver® directed evolution technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other proteins. These enzymes are engineered and optimized for specific functions and characteristics, enabling them to survive challenging environments or perform unique biochemical transformations. Company X applies its technology and expertise to enhance enzyme properties and performance, driving improvements in the manufacturing of complex therapeutics across two key areas: its ECO Synthesis manufacturing platform and its small molecule pharma biocatalysis business. The ECO Synthesis® manufacturing platform consists of enzymatic tools and processes designed for the large-scale manufacture of RNA interference ("RNAi") therapeutics. The CodeEvolver platform technology is used to develop enzymes for RNAi therapeutic synthesis, leading to improvements in purity, yield, and manufacturing efficiency. In November 2024, Company X presented data at the TIDES Europe conference, demonstrating the successful end-to-end enzymatic synthesis of an entire commercially approved small interfering ribonucleic acid ("siRNA") therapeutic asset using the ECO Synthesis manufacturing platform. This included full enzymatic sequential synthesis, adding one nucleotide at a time, and three other routes utilizing enzymatic ligation with their double-stranded RNA ("dsRNA") ligase. For these three routes, data showed that full-length oligonucleotides of equal quality and yields were obtained whether fragments were made with enzymes or by traditional solid phase oligonucleotide synthesis ("SPOS").

Codexis, Inc. (NASDAQ:CDXS) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 12 items for CDXS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 12 most recent items scored 7 or higher, the top rating is 9/10, with 2 rated 8 or above. Recent SEC coverage for CDXS spans 10-Q, 8-K, 10-K.

Recent high-impact activity:

  • Codexis Posts $15.7M Q3 Product Revenue, Narrower $8.1M Net Loss
  • Codexis Refinances Debt With $60M Trinity Capital Term Loan
  • Codexis Signs siRNA Innovator to Test ECO Synthesis Platform for Stereo-Defined Fragments
  • Codexis Q2 Revenue Jumps 79% on Enzyme Sales, Loss Narrows; Cash Runway Extended to 2028
  • Codexis Posts Q2 2026 Revenue of $14.9M, Reaffirms Full-Year Outlook, and Pushes Cash Runway to 2028

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$70.39M
Net Income
-$43.97M
Diluted EPS
-$0.50
Op. Cash Flow
-$19.38M
Free Cash Flow
-$23.85M
Gross Profit
$61.05M
Operating Income
-$41.74M
Cash & Equivalents
$50.79M
Total Debt
$40.1M
Debt / Equity
0.79×
Net Margin
-62.5%
Shares Outstanding
90.48M sh
Source: 10-K · filed 2026-03-11 · accession 0001200375-26-000006

Short Interest & Short Volume

4.89 days to cover

FINRA reported short interest of 4,398,917 shares in CDXS as of the October 30, 2026 settlement, a 11.2% decrease from the prior period — about 4.9 days to cover at its recent average daily volume. On November 20, 2026, 63.1% of CDXS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)4,398,917 shares as of October 30, 2026
Change vs prior period▼ 11.2%
Days to cover4.89 at avg daily volume of 898,826
Daily short volume (FINRA facilities)63.1% of 1,395,723 shares on November 20, 2026
5-day average short volume64.5%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for CDXS, detected from its recent SEC filings · based on capital-structure filings through 2026-07-27.

1 recent capital raise

Offering Terms Confirmed · Use of Proceeds

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with C →
$0.91 -9.90% today
52-week range · as of 2026-08-11 $0.91 – $3.87
Market cap
$110.69M
Volume
2.1M (2.0× avg)
3-mo avg 1M
Live data · 2026-11-21 20:53 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CDXS - Latest Insights

CDXS
Nov 12, 2026, 4:06 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $0.9948
Real-time Price: $0.910 info
Change: -$0.0848 (-9%) info
Market Cap: $110.694M info
CDXS
Nov 10, 2026, 6:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.11
Real-time Price: $0.910 info
Change: -$0.200 (-18%) info
Market Cap: $110.694M info
CDXS
Sep 28, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.44
Real-time Price: $0.910 info
Change: -$0.530 (-37%) info
Market Cap: $110.694M info
CDXS
Aug 11, 2026, 4:21 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.51
Real-time Price: $0.910 info
Change: -$0.595 (-40%) info
Market Cap: $110.694M info
CDXS
Aug 11, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.55
Real-time Price: $0.910 info
Change: -$0.640 (-41%) info
Market Cap: $110.694M info
CDXS
Jul 27, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.55
Real-time Price: $0.910 info
Change: -$0.640 (-41%) info
Market Cap: $110.694M info
CDXS
Jul 24, 2026, 6:24 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $1.49
Real-time Price: $0.910 info
Change: -$0.5797 (-39%) info
Market Cap: $110.694M info
CDXS
Jul 23, 2026, 11:48 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $1.58
Real-time Price: $0.910 info
Change: -$0.670 (-42%) info
Market Cap: $110.694M info
CDXS
Jul 23, 2026, 4:13 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.61
Real-time Price: $0.910 info
Change: -$0.700 (-43%) info
Market Cap: $110.694M info
CDXS
May 07, 2026, 4:20 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.70
Real-time Price: $0.910 info
Change: -$1.79 (-66%) info
Market Cap: $110.694M info
CDXS
Mar 11, 2026, 4:39 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $1.65
Real-time Price: $0.910 info
Change: -$0.740 (-45%) info
Market Cap: $110.694M info
CDXS
Mar 11, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $1.74
Real-time Price: $0.910 info
Change: -$0.830 (-48%) info
Market Cap: $110.694M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets